Prices delayed by at least 15 minutes | Print
Invesco Markets Ii PLC IVZ S&P WLD HEALTH ESG UCITS ETF ACC (WHCG)
Open
419.90p
Previous close
424.025p
Trade high
424.35p
Income frequency
-
Year low
402.50p
Year high
516.70p
Replication method
Physical Full
Volume
1,895
Type
ETF
UCITS
Yes
Dividend yield
–
Ongoing charge
0.18
ISIN
IE000L4EH2K5
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Regular investment and Dividend reinvestment
Before investing please read:
Share price
Asset allocation
Top 10 holdings
Holdings 13/03/2025 | % of assets |
---|---|
Eli Lilly and Co | 10.34 |
AbbVie Inc | 9.95 |
UnitedHealth Group Inc | 6.89 |
Roche Holding AG | 5.19 |
Abbott Laboratories | 4.87 |
AstraZeneca PLC | 4.33 |
Merck & Co Inc | 3.93 |
Novo Nordisk AS Class B | 3.30 |
Novartis AG Registered Shares | 3.29 |
Gilead Sciences Inc | 3.06 |
Investment objective
The investment objective of the Fund is to achieve the net total return of the S&P Developed Ex-Korea LargeMidCap ESG Enhanced Health Care Index (the "Reference Index") less fees, expenses and transaction costs.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.
Asset class
ETFMorningstar ratingTM
Morningstar sustainability ratingTM
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.